Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q3 2022 · 10-Q
Revenue$4.87M$4.87M+72.3% vs Q3 2021 Net Income-$5.14M-$5.14MN/M vs Q3 2021 EPS Diluted-$0.14-$0.14no prior Q3 2021 on file Gross Profit$1,768,600+115.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,716,801N/M Free Cash Flowderived-$3,762,221— Margins · derivedGross margin36.3%+7.3 pt vs Q3 2021
Operating margin-104.9%+322.0 pt vs Q3 2021
Net margin-105.6%+324.8 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end